CRBU - 3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond
2023-07-28 08:30:00 ET
With shares of Caribou Biosciences (NASDAQ: CRBU) up by 51% in the past 30 days, there's more than one reason why you might want to consider a purchase for yourself. Between its recent release of some great early-stage data from its flagship program and its powerful technology platform, this biotech might be going places.
So let's dive into the specifics a bit more and examine three reasons why Caribou is a screaming buy in July and beyond.
Caribou's most advanced program is called CB-010, and it's being investigated in a phase 1 clinical trial for treating relapsed or refractory B-cell non-Hodgkin's lymphoma. On July 13, the biotech reported that 44% of the 16 patients in the trial had experienced a complete response to the therapy, rendering them free of detectable cancer for more than six months. In total, 94% of the patients responded to the treatment for at least some period of time, and there were very few reports of severe side effects.
For further details see:
3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond